Enhanced Angiotensin II Activity in Heart Failure

Publisher Website
Google Scholar
Abstract
—There are strong data favoring the pathogenic role of angiotensin II type 1 receptor (AT 1 ) activation with subsequent promotion of myocyte growth and cardiac fibrosis in the development of cardiac hypertrophy and heart failure. An emerging hypothesis suggests that the activity of the angiotensin II type 2 receptor (AT 2 ) may counterregulate AT 1 receptor effects during cardiac development and during the evolution of cardiac hypertrophy and heart failure. In this review, we examine the potential role of AT 2 activity in the context of this hypothesis. In contrast to the counterregulatory hypothesis, studies in mice with an overabundance of, or a deficiency in, the AT 2 receptor do not suggest that AT 2 signaling is essential for cardiac development. Moreover, the proposed antigrowth effects of AT 2 receptor signaling in pathological cardiac hypertrophy could not be shown in two mice models both deficient in AT 2 receptors. The role of AT 2 receptor signaling in cardiac fibrosis is, however, still debatable because of conflicting data in the same two studies. In angiotensin II–evoked apoptosis in cardiomyocytes, the proposed proapoptotic role of AT 2 activity could not be confirmed. Furthermore, in the progression from the bench to bedside, the results of two large clinical trials in heart failure, namely ELITE II and Val-HeFT, can be explained without ascribing a major protective role to the unopposed activity of the AT 2 receptor in the failing myocardium. In this review, we conclude that the collective evidence does not strongly support a net beneficial effect of AT 2 stimulation in the diseased myocardium.

This publication has 16 references indexed in Scilit: